Pfizer is undervalued, trading just over 8x 2026 earnings, with improving dividend yield and core business fundamentals.

Earlier this week, Pfizer reported that its Phase 3 SigVie-002 trial of sigvotatug vedotin in previously treated non-squamous non-small cell lung cancer failed to show a statistically significant ...

In the overall population, sigvotatug vedotin did not demonstrate a statistically significant improvement in overall survival compared with chemotherapy medicine docetaxel.

Pfizer’s high-stakes bet on antibody-drug conjugates (ADCs) has hit a speed bump. The pharma giant announced Monday that sigvotatug vedotin, the first new ADC to read out pivotal data following its ...

Pfizer reported a 2% decline in revenue and 4% increase in adjusted EPS in 2025, and management maintained 2026 revenue guidance for $59.5 billion-$62.5 billion (between flat and a 5% decline) and ...

About a month after Pfizer CEO Albert Bourla, Ph.D., told investors that the Big Pharma’s pipeline pruning was mostly done, the company has trimmed another branch. Pfizer has scrapped a phase 1 ...

Pfizer (NYSE:PFE) reported that its late stage lung cancer drug sigvotatug vedotin did not significantly improve overall survival in a pivotal Phase 3 trial. The trial compared sigvotatug vedotin to ...

Pfizer's oncology ambitions could start to take shape next year. The drugmaker is also likely to make progress in the weight-loss market. It might take a while longer, but Pfizer is on the path to ...

Pfizer PFE and AstraZeneca AZN are global pharmaceutical leaders with a strong presence in oncology. For Pfizer, oncology is ...